The striking benefits achieved with emerging treatment options for recalcitrant connective tissue diseases offer the ...

Eight children with severe autoimmune diseases who did not respond to conventional therapies were able to completely stop ...

CONGRESSWOMAN Girlie Veloso of Malasakit@Bayanihan Party-list filed House Bill (HB) 7302 in the House of Representatives on ...

New findings from a Phase II study indicate that antenatal treatment with the FcRn blocker nipocalimab resulted in low fetal drug exposure and transient reductions in infant IgG levels at birth, ...

AbbVie Inc. stays a Strong Buy after a Q4 2025 earnings beat led by HUMIRA, plus growth in immunology and neuroscience. Click ...

Hospital for Special Surgery (HSS) today announced the appointment of Anca Dinu Askanase, MD, MPH, as the new Chair of the Department of Medicine and Chief of the Division of Rheumatology, effective ...

AbbVie has submitted applications to the FDA and EMA for new indications for upadacitinib (RINVOQ 15-mg) for the treatment of adult and adolescent patients living with non-segmental vitiligo (NSV), ...

This autoimmune disease may impact your skin as well as your nails and hair. Learn what to look for to treat lupus more effectively.

Driving AUCATZYL® top line growth Optimizing manufacturing operation to improve gross margin and innovating on next generation manufacturing platform Progressing the CATULUS, LUMINA and BOBCAT trials ...

Both platforms are backed by over 50 peer-reviewed publications representing decades of development. The addressable markets span multiple areas: Alzheimer's disease ($32.8 billion by 2033), ...

Submissions are supported by data from the Phase 3 Viti-Up clinical studies demonstrating upadacitinib achieved the co-primary endpoints of at least a 50% improvement ...